EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Inhaled nucleic acid therapeutics for respiratory diseases: delivery barriers, translational challenges, and emerging solutions

Leijie Yu, Chongrui Zhou, Xiang Cheng, Xia Zhao, Xingru Yi, Yaqin Tang, Keyu Su, Fangyu Qiao, Jing Xie, Robert J Lee

Precision Clinical Medicine · 21.10.2026 · 9 (4)

DOI: 10.1093/pcmedi/pbag030 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Precision Clinical Medicine, online erschienen am 24.10.2026. Verfasst von Leijie Yu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Nanomedicine and Gene Therapy, School of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing 400054, China. Die Arbeit nennt 239 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Science and Technology Research Program of Chongqing Education Commission of China, Chongqing Science and Technology Commission of China, National Foreign Experts Individual Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pulmonary delivery of nucleic acid therapeutics represents a transformative strategy for treating a broad spectrum of respiratory diseases, including lung cancer, pulmonary fibrosis, chronic obstructive pulmonary disease, and acute lung injury. Despite their promise, effective clinical translation is hampered by a cascade of physiological barriers spanning the airway mucus layer, mucociliary clearance, alveolar macrophage uptake, cellular internalization, and endosomal sequestration. In this review, we adopt a barrier-oriented framework to systematically dissect these extracellular, cellular, and intracellular obstacles, highlighting how disease-specific microenvironments further modulate delivery efficiency. We then critically examine emerging engineering strategies—including nanocarrier surface modifications, biomimetic vesicles, aerosol optimization, and stimuli-responsive formulations that are designed to overcome these barriers. Integrating mechanistic insights with disease-specific considerations, we analyze how distinct pulmonary pathologies necessitate tailored delivery solutions, emphasizing that successful translation requires coupling nanoengineering with the unique cellular and molecular landscapes of target tissues. Finally, we discuss translational challenges, including manufacturing scalability, long-term safety, and regulatory constraints, and outline emerging solutions that may enable next-generation inhaled nucleic acid therapies. By providing a synthesis of barrier-oriented design principles and disease-driven targeting strategies, this review offers a comprehensive roadmap for accelerating the clinical adoption of inhaled nucleic acid therapeutics.

Schlagwörter

Stichwörter der Autor:innen

biological barriersdisease-specific targetinginhaled RNA therapeuticsnanocarrierspulmonary deliverytranslational challenges

Autor:innen und Institutionen

  • Center for Nanomedicine and Gene Therapy, School of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing 400054, China.
  • School of Public Health, Chongqing Medical University, Chongqing 401331, China.
  • The WhiteOak Group, Inc., Rockville, MD 20855, USA.

Förderung

  • Science and Technology Research Program of Chongqing Education Commission of China
  • Chongqing Science and Technology Commission of China
  • National Foreign Experts Individual Program
  • Graduate Scientific Research and Innovation Foundation of Chongqing of PR China

Zitieren

APA

Yu, L., Zhou, C., Cheng, X., Zhao, X., Yi, X., Tang, Y., Su, K., Qiao, F., Xie, J., & Lee, R. J. (2026). Inhaled nucleic acid therapeutics for respiratory diseases: delivery barriers, translational challenges, and emerging solutions. Precision Clinical Medicine, 9(4). https://doi.org/10.1093/pcmedi/pbag030

Vancouver

Yu L, Zhou C, Cheng X, Zhao X, Yi X, Tang Y, et al. Inhaled nucleic acid therapeutics for respiratory diseases: delivery barriers, translational challenges, and emerging solutions. Precision Clinical Medicine. 2026;9(4). doi:10.1093/pcmedi/pbag030

BibTeX
@article{Yu2026,
  author = {Yu, Leijie and Zhou, Chongrui and Cheng, Xiang and Zhao, Xia and Yi, Xingru and Tang, Yaqin and Su, Keyu and Qiao, Fangyu and Xie, Jing and Lee, Robert J},
  title = {Inhaled nucleic acid therapeutics for respiratory diseases: delivery barriers, translational challenges, and emerging solutions},
  journal = {Precision Clinical Medicine},
  year = {2026},
  volume = {9},
  number = {4},
  doi = {10.1093/pcmedi/pbag030}
}
Kostenlos starten →